3SBio (HK:1530) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
3SBio Inc.’s subsidiary, Sunshine Mandi, has inked a lucrative cooperation agreement with Hybio Pharmaceutical for the joint development and exclusive supply of Semaglutide Injection, a weight management product. Under the deal, Sunshine Mandi is set to make milestone payments up to RMB 270 million to Hybio, including preclinical results, exclusive purchase prices, and profit-based royalties. The partnership aims to market and commercialize the product, with Sunshine Mandi holding exclusive marketing rights in certain regions and Hybio handling production.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.